SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC

Bookmark and Share
Published: 10 Jul 2019
Views: 427
Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA

Dr Benjamin Soloman speaks to ecancer at the WIN 2019 Symposium in Paris about the ongoing phase I/II SPRING 01 study, which focuses on patients with advanced, metastatic non-small cell lung cancer (NSCLC).

He explains the design of the trial, which includes the use of transcriptomics and genomics to predict therapeutic response to avelumab, axitinib and palbociclib in both normal and tumour tissue.

Dr Soloman also describes the second phase of the study, which involves enrolling patients in the first-line setting and mentions that this study could be expanded to other disease types in the future.